ARTICLE | Clinical News

SL-401: Phase I/II started

October 27, 2014 7:00 AM UTC

Stemline began an open-label, U.S. Phase I/II trial of IV SL-401 given for 5 consecutive days in 28-day cycles for >=6 cycles in about 35 adults with AML in first complete remission with MRD and who are at high risk for relapse. The first part will evaluate 3 doses of SL-401 in about 6-9 patients to determine the dose for the second part, which will evaluate the dose in about 24-29 patients. ...